

Appendix Two: Emetic Potential of Common Chemotherapy Regimens

Minimal Emetic Potential (MinEC)	Low Emetic Potential (LEC)	Moderate Emetic Potential (MEC)	High Emetic Potential (HEC)
<p>Alemtuzumab</p> <p>ALL induction (vincristine, asparaginase, dexamethasone +/- daunorubicin)</p> <p>Asparaginase (IM or IV)^</p> <p>Mercaptopurine (oral)</p> <p>Methotrexate (oral)</p> <p>Tioguanine (oral)</p> <p>Dexrazoxane</p> <p>Rituximab</p>	<p>COP (cyclophosphamide, vincristine, prednisone)</p> <p>Etoposide</p> <p>PEMGEM (pemetrexed, gemcitabine)</p> <p>Triple intrathecal therapy (methotrexate, hydrocortisone, cytarabine)</p> <p>Vinblastine</p> <p>Vincristine</p> <p>Vinorelbine</p>	<p>ADE (cytarabine, daunorubicin, etoposide)</p> <p>AE (cytarabine, etoposide)</p> <p>MA (mitoxantrone, cytarabine)</p> <p>OEPA (vincristine, etoposide, prednisone, doxorubicin)</p> <p>VA (vincristine, actinomycin)</p> <p>ALL HDMTX (methotrexate 5gm²)</p> <p>COPADM (cyclophosphamide, vincristine, prednisone, doxorubicin, methotrexate)</p> <p>CYM (cytarabine, methotrexate)</p> <p>TPCV (tioguanine, procarbazine, CCNU (lomustine), vincristine)</p> <p>VC (vincristine, carboplatin)</p> <p>TOPO/CPM (topotecan, cyclophosphamide)</p> <p>HSCT regimens[#]</p>	<p>Asparaginase (IV Erwinia)</p> <p>BEAM (carmustine, etoposide, cytarabine, melphalan)</p> <p>Cisplatin (any regimen)</p> <p>COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine)</p> <p>CYVE (cytarabine, etoposide)^{&}</p> <p>IE (ifosfamide & etoposide)</p> <p>IVA (ifosfamide, vincristine, actinomycin)^{&}</p> <p>IVA-Do (ifosfamide, vincristine, actinomycin, doxorubicin)</p> <p>Osteosarcoma HDMTX (methotrexate ≥12 g/m²)^{&}</p> <p>VAC (vincristine, actinomycin, cyclophosphamide)^{&}</p> <p>VDC (vincristine, doxorubicin, cyclophosphamide)</p>

Note: Table is intended as a guide only; all agents given intravenously (IV) unless stated otherwise

[&] In adolescents and older children this combination may cause significant vomiting, consider classing as high emetic potential

[^] Exception IV Asparaginase (Erwinia)

[#] Dependent on HSCT regimen, may be classed as moderate or high emetic potential

Adapted from the Royal Children's Hospital, Melbourne (2014), National Child Cancer Network, New Zealand (2019), Children's Oncology Group (2022) & Sing et al (2019)